SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-349022
Filing Date
2021-12-06
Accepted
2021-12-06 16:16:01
Documents
12
Period of Report
2021-12-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d203828d8k.htm   iXBRL 8-K 25182
  Complete submission text file 0001193125-21-349022.txt   147721

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kpti-20211202.xsd EX-101.SCH 2885
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20211202_lab.xml EX-101.LAB 18138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20211202_pre.xml EX-101.PRE 11403
5 EXTRACTED XBRL INSTANCE DOCUMENT d203828d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 211473383
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences